Clinical Trials

Sponsor: SWOG

Sponsor Study ID: S1803

Study Title: Phase III Study of Daratumumab/rHuPH20 (NSC 810307) + Lenalidomide or Lonalidomide as Post Autologous STem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration

CTO #: 103174

NCT Number: NCT04071457

Phase: III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Multiple Myeloma

Study Objectives: To compare overall survival (OS) between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma (MM) patients. To compare the best overall response rate (ORR), including partial remission (PR), very good partial remission (VGPR), and complete remission (CR, sCR) in the subset of patients not in PR at randomization to lenalidomide versus lenalidomide + daratumumab/rHuPH20 in this patient population.

Study Documents    
(MUSC NetID required for document access)